why choose us

First received: January 03, 2023

Clinical Trial: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Idiopathic Pulmonary Fibrosis

Study Type: INTERVENTIONAL


Official Title: REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pu

Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

Read more